ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $107,000 | +25.9% | 4,320 | +13.7% | 0.01% | +20.0% |
Q2 2020 | $85,000 | +8400.0% | 3,800 | +280.0% | 0.01% | – |
Q3 2019 | $1,000 | -99.3% | 1,000 | -71.4% | 0.00% | -100.0% |
Q1 2019 | $150,000 | +2042.9% | 3,500 | +3400.0% | 0.02% | +1500.0% |
Q4 2018 | $7,000 | -82.5% | 100 | -98.4% | 0.00% | -66.7% |
Q3 2018 | $40,000 | -54.0% | 6,100 | +281.2% | 0.00% | -57.1% |
Q2 2018 | $87,000 | +85.1% | 1,600 | -8.6% | 0.01% | +75.0% |
Q1 2018 | $47,000 | +1466.7% | 1,750 | +457.3% | 0.00% | – |
Q3 2017 | $3,000 | -92.7% | 314 | -96.9% | 0.00% | -100.0% |
Q2 2017 | $41,000 | – | 10,200 | +1033.3% | 0.00% | – |
Q1 2017 | $0 | -100.0% | 900 | +50.0% | 0.00% | – |
Q4 2016 | $2,000 | -33.3% | 600 | -90.2% | 0.00% | – |
Q3 2016 | $3,000 | -97.7% | 6,100 | -44.0% | 0.00% | -100.0% |
Q2 2016 | $129,000 | +279.4% | 10,900 | +222.5% | 0.01% | +250.0% |
Q1 2016 | $34,000 | -72.4% | 3,380 | -55.4% | 0.00% | -71.4% |
Q4 2015 | $123,000 | – | 7,580 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |